Fintel reports that on January 7, 2026, B of A Securities upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Underperform to Buy.
Analyst Price Forecast Suggests 4.08% Upside
As of December 21, 2025, the average one-year price target for Regeneron Pharmaceuticals is $808.25/share. The forecasts range from a low of $633.27 to a high of $1,109.85. The average price target represents an increase of 4.08% from its latest reported closing price of $776.54 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Regeneron Pharmaceuticals is 13,791MM, a decrease of 3.21%. The projected annual non-GAAP EPS is 48.25.
What is the Fund Sentiment?
There are 2,184 funds or institutions reporting positions in Regeneron Pharmaceuticals. This is an decrease of 79 owner(s) or 3.49% in the last quarter. Average portfolio weight of all funds dedicated to REGN is 0.30%, an increase of 2.61%. Total shares owned by institutions decreased in the last three months by 2.68% to 107,026K shares. 
The put/call ratio of REGN is 0.50, indicating a bullish outlook.
What are Other Shareholders Doing?
Dodge & Cox holds 4,551K shares representing 4.52% ownership of the company. In its prior filing, the firm reported owning 3,826K shares , representing an increase of 15.92%. The firm increased its portfolio allocation in REGN by 22.32% over the last quarter.
Jpmorgan Chase holds 4,072K shares representing 4.04% ownership of the company. In its prior filing, the firm reported owning 3,940K shares , representing an increase of 3.26%. The firm increased its portfolio allocation in REGN by 1.43% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 3,416K shares representing 3.39% ownership of the company. In its prior filing, the firm reported owning 3,396K shares , representing an increase of 0.58%. The firm decreased its portfolio allocation in REGN by 25.72% over the last quarter.
VFINX - Vanguard 500 Index Fund Investor Shares holds 2,948K shares representing 2.93% ownership of the company. In its prior filing, the firm reported owning 2,922K shares , representing an increase of 0.87%. The firm decreased its portfolio allocation in REGN by 25.82% over the last quarter.
Geode Capital Management holds 2,536K shares representing 2.52% ownership of the company. In its prior filing, the firm reported owning 2,465K shares , representing an increase of 2.79%. The firm decreased its portfolio allocation in REGN by 46.73% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
